Moderna vs Pfizer
Pfizer reported revenue of $62.6 billion in fiscal 2025, 32.2 times Moderna's $1.9 billion in fiscal 2025. Moderna's revenue fell 39.9% in its latest year, and Pfizer's fell 1.6%. Free cash flow was −$2.1 billion at Moderna and $9.1 billion at Pfizer.
Side by side
| Moderna | Pfizer | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.9B | $62.6B |
| Revenue growth | −39.9% | −1.6% |
| Revenue growth a year, last 5 years | 19.3% | 8.5% |
| Gross margin | 55.4% | 74.3% |
| Operating margin | −158.1% | — |
| Net margin | −145.2% | 12.4% |
| Free cash flow | −$2.1B | $9.1B |
| Free cash flow margin | −106.2% | 14.5% |
| Return on capital | −65.4% | 7.2% |
| Net debt to EBITDA | — | 3.2x |
| Dividends and buybacks | $2M | $9.8B |
| Change in diluted share count | 1.3% | 0.2% |
| Last close | $199.33 | $27.54 |
| P/E at the last close | — | 39.3× |
| Insider trades, last 12 months | sold $98.5 million | bought $3.0 million, sold $134,661 |
| Piotroski F-score | 2 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ModernaPfizer
Operating margin
Percent of revenue
ModernaPfizer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ModernaPfizer